title: Assessment of antimicrobial (host defense) peptides as anti-cancer agents.
abstract: Cationic antimicrobial (host defense) peptides (CAPs) are able to kill microorganisms and cancer cells, leading to their consideration as novel candidate therapeutic agents in human medicine. CAPs can physically associate with anionic membrane structures, such as those found on cancer cells, causing pore formation, intracellular disturbances, and leakage of cell contents. In contrast, normal cells are less negatively-charged and are typically not susceptible to CAP-mediated cell death. Because the interaction of CAPs with cells is based on charge properties rather than cell proliferation, both rapidly dividing and quiescent cancer cells, as well as multidrug-resistant cancer cells, are targeted by CAPs, making CAPS potentially valuable as anti-cancer agents. CAPs often exist as families of peptides with slightly different amino acid sequences. In addition, libraries of synthetic peptide variants based on naturally occurring CAP templates can be generated in order to improve upon their action. High-throughput screens are needed to quickly and efficiently assess the suitability of each CAP variant. Here we present the methods for assessing CAP-mediated cytotoxicity against cancer cells (suspension and adherent) and untransformed cells (measured using the tritiated thymidine-release or MTT assay), and for discriminating between cell death caused by necrosis (measured using lactate dehydrogenase- or (51)Cr-release assays), or apoptosis and necrosis (single-stranded DNA content measured by flow cytometry). In addition the clonogenic assay, which assesses the ability of single transformed cells to multiply and produce colonies, is described.
authors.affiliation: Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada.
authors.forename: Susan
authors.initials: S
authors.lastname: Douglas
authors.forename: David W
authors.initials: DW
authors.lastname: Hoskin
authors.forename: Ashley L
authors.initials: AL
authors.lastname: Hilchie
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002999:Clone Cells; D004247:DNA / Q000378:metabolism; D005434:Flow Cytometry; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D010455:Peptides / Q000378:metabolism / Q000494:pharmacology*; D013535:Suspensions; D013936:Thymidine / Q000378:metabolism; D014316:Tritium / Q000378:metabolism
chemical_list: D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D010455:Peptides; D013535:Suspensions; D014316:Tritium; D004247:DNA; D007770:L-Lactate Dehydrogenase; D013936:Thymidine